Understanding relative survival outcomes for patients with cutaneous T-cell lymphoma (CTCL) subtypes mycosis fungoides and Sézary syndrome treated with mogamulizumab or vorinostat: combining Australian real-world evidence and MAVORIC phase 3 trial data.

Remák, Edit; Hawkins, Neil; Jones, Trefor; Otley, Marissa; Twigger, Robert; Prince, Miles

Remák, Edit; Hawkins, Neil; Jones, Trefor; Otley, Marissa; Twigger, Robert; Prince, Miles.

Afiliación

Remák E; Visible Analytics Ltd., Budapest, Hungary.
Hawkins N; Visible Analytics Ltd., Oxford, United Kingdom.
Jones T; Kyowa Kirin International, London, United Kingdom.
Otley M; Kyowa Kirin Australia Pty Ltd., Sydney, Australia.
Twigger R; Peter MacCallum Cancer Centre, Melbourne, Australia.
Prince M; Peter MacCallum Cancer Centre, Melbourne, Australia.

Eur J Cancer ; 156 Suppl 1: S18, 2021 Oct.

Article en En | MEDLINE | ID: mdl-34649645

Palabras clave

Sézary syndrome; cutaneous T-cell lymphoma; mycosis fungoides; overall survival; real-world evidence

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Idioma: En Revista: Eur J Cancer Año: 2021 Tipo del documento: Article País de afiliación: Hungria

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google